Relation between serum myostatin with BMI and PaO₂/PaCO₂ in patients with chronic obstructive pulmonary disease.
10.3969/j.issn.1672-7347.2014.08.009
- Author:
Xiufang WEN
1
;
Pian LIU
;
Haiqiao WU
;
Xiangdong ZHOU
Author Information
1. Department of Respiratory Medicine, Third People's Hospital of Chongqing, Chongqing 400014,China.
- Publication Type:Journal Article
- MeSH:
Blood Gas Analysis;
Body Mass Index;
Humans;
Male;
Monitoring, Physiologic;
Myostatin;
blood;
Prognosis;
Pulmonary Disease, Chronic Obstructive;
blood
- From:
Journal of Central South University(Medical Sciences)
2014;39(8):807-810
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To determine the relation between serum myostatin with body mass index (BMI) and PaO₂/PaCO₂ in men with chronic obstructive pulmonary disease (COPD).
METHODS:A cohort of outpatients with stable COPD was evaluated. We evaluated the myostatin, PaO₂/PaCO₂ and BMI, and the patients were stratified by BMI. The plasma level of myostatin and PaO₂/PaCO₂ was measured by high sensitivity ELISA or blood gas analysis.
RESULTS:PaCO₂ and myostatin increased significantly compared with those in the control group (P<0.05), but PaO₂ decreased significantly. There was positive correlation between myostatin and PaCO₂ (P<0.05), and negative correlation between myostatin and BMI/FEV1/pred value/PaO₂ (P<0.05).
CONCLUSION:Patients with higher myostatin levels had a lower BMI, lower PaO₂ and higher PaCO₂, with poor pathogenetic condition and prognosis. Myostatin may be a potential treatment target in patients with chronic obstructive pulmonary disease.
